with an antibody, peptide, or nonpeptide chemical.--

--15. (Amended) The method of [any one of claims 1-9] claim 1, which comprises inhibiting kit dimerization with an antibody, peptide, or nonpeptide chemical.--

--16. (Amended) The method of [any one of claims 1-9] claim 1, wherein downstream signaling of the kit activation pathway is inhibited by blocking substrate association with kit kinase domain.--

--17. (Amended) The method of [any one of claims 1-9] claim 1, wherein downstream signaling of the kit activation pathway is inhibited by blocking enzymatic function in the downstream signaling pathway.--

--18. (Amended) The method of [any one of claims 1-9] claim 1, wherein downstream signaling of the kit activation pathway is inhibited by blocking binding of molecules in the downstream signaling pathway.--

--19. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound is an antibody or portion thereof.--

--23. (Amended) The method of claim [22] 19, wherein the [anti-kit] antibody is ACK2.--

--24. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises a Fab

fragment of an anti-kit antibody.--

--25. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises the variable domain of an anti-kit antibody.--

--26. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises one or more CDR portions of an anti-kit antibody.--

--28. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises a peptide, peptidomimetic, a nucleic acid, or an organic compound with a molecular weight less than 500 Daltons.--

--29. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound is sSCF, sKIT ligand or a fragment thereof.--

--30. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound is sKIT or a fragment thereof.--

--31. (Amended) The method of [any one of claims 1-9] claim 1, wherein the subject is a mammal.--

--33. (Amended) The method of [any one of claims 1-9] claim 1, wherein the administration is intralesional, intraperitoneal, intramuscular, subcutaneous, intravenous, liposome mediated delivery, transmucosal, intestinal, topical, nasal, oral, anal, ocular or otic delivery.